Mangalam Drugs & Organics (BOM:532637) EPS (Basic): ₹-28.05 (TTM As of Mar. 2026)


BOM:532637 Mangalam Drugs & Organics Ltd BOM:532637
40 GF Score
Price ₹28.70
GF Value ₹64.65
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics EPS (Basic)?

Mangalam Drugs & Organics BOM:532637 -1.17% 40 EPS (Basic) is ₹-28.05 as of Mar. 2026. GuruFocus rates BOM:532637 with a GF Score™ of 40/100 and a GF Value™ of ₹64.65 (Possible Value Trap). The stock has 4 warning signs investors should review.

Mangalam Drugs & Organics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹-8.48. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-28.05.

Mangalam Drugs & Organics's EPS (Diluted) for the three months ended in Mar. 2026 was ₹-8.48. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-28.05.

Mangalam Drugs & Organics's EPS without NRI for the three months ended in Mar. 2026 was ₹-8.48. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -28.05.

During the past 12 months, Mangalam Drugs & Organics's average EPS without NRIGrowth Rate was -760.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Mangalam Drugs & Organics's highest 3-Year average EPS without NRI Growth Rate was 113.30% per year. The lowest was -46.40% per year. And the median was -5.80% per year.

Mangalam Drugs & Organics  (BOM:532637) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Mangalam Drugs & Organics EPS (Basic) Related Terms

Mangalam Drugs & Organics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics EPS (Basic) Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.42 0.80 -5.73 4.25 -28.05

Mangalam Drugs & Organics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 -8.72 -4.64 -6.21 -8.48
BOM:532637
40GF Score
Mangalam Drugs & Organics Ltd BOM:532637
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Mangalam Drugs & Organics's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-444-0)/15.829
=-28.05

Mangalam Drugs & Organics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-134.2-0)/15.825
=-8.48

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-28.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹-28.05 mean?
Mangalam Drugs & Organics (BOM:532637) has a EPS (Basic) of ₹-28.05 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' EPS (Basic) too high?
Mangalam Drugs & Organics' current EPS (Basic) is ₹-28.05. Overall, Mangalam Drugs & Organics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' EPS (Basic) compare to ZTS?
Mangalam Drugs & Organics' EPS (Basic) of ₹-28.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current EPS (Basic) is ₹-28.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (BOM:532637) is currently considered Possible Value Trap. The stock's GF Value™ is ₹64.65, compared to a current price of ₹28.70 — trading 55.6% below its estimated fair value. The current EPS (Basic) is ₹-28.05. Mangalam Drugs & Organics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Mangalam Drugs & Organics (BOM:532637), the current EPS (Basic) is ₹-28.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (BOM:532637) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹28.70 is trading 55.6% below its estimated GF Value™ of ₹64.65. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for BOM:532637:

  • EPS (Basic): ₹-28.05
  • GF Value™: ₹64.65 vs. price of ₹28.70 (55.6% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the BOM:532637 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges MANGALAM:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
40GF Score

Get the complete analysis for BOM:532637

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹28.70
Price
₹64.65
GF Value